Biogen Inc BIIB

Champion-Vibe

MID-TERM: Double bottom at an iceline with a breakout of a falling wedge and a double bottom on a wave of classic bullish divergence. (not financial advice)

IvanLabrie

I think it warrants making a new publication here, $BIIB has flashed a buy signal with tremendously good reward to risk, as it can resume the long term trend that can take it over $1600-2600 over time. Phase 3 clinical trials have gone really well for their Alzheimer's treatment 'Aduhelm', putting it in line with results obtained by $LLY's drug 'Donanemab'. I was...

TizyCharts

Larger Stop at 260 Closer stop at 273 Bullish cross already happened. The Daily (yellow) EMA didn't work much in the past, but always keep stop closer. RSI testing the average.

UndergroundAnalyst

All trade in sell order/buy order, might not trigger, cancel if the price has run too far.

EW_T

We are in wave 5 on biib, question is can we get continuation to 282 or maybe 269

meanweimaraner

$BIIB inverse head and shoulders formation target $152+ short term

Davis_Stocks

If BIIB can close above the trend line it will show a new bull run

IvanLabrie

Reward to risk long term in $BIIB is very attractive here. I've gone long via a calendar spread before the latest FDA approval news, which turned out like a good long position when Biogen's Alzheimer's drug Aduhelm received accelerated approval. Following this, related companies which also have Alzheimer's drugs pending approval (like $LLY) received a dramatic...

GregFolin

BIIB blasted through long-term resistance on the huge news of the company's approval for a first-of-its-kind Alzheimer's treatment. This is a multi-billion-dollar market with effectively no competition.

Coin1t1v3

re

UndergroundAnalyst

If you took my analysis, you might have closed the trade early, for those who havnt, now is the best time to close your trade. The buy entry was given on 8th April at 265.35 with stop loss at 249.68 (ard 1600pips risk), the price went up to 431.71, as much as 16000 pips profit, 10 times the risk. I dont trade fundamentally, most of the financial figure only start...

RocketTickers

BIIB: Biogen Inc. 2021-06-07 13:00:00 FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

FreddyStradlin

Sell 50% of position at $350, 25% at $360, the remaining just let it fly.

poggo_

Its about to fill gap fully after halt. $320 target price.

MarketMiracleAdvisor

Certainly the "to the moon" for an established company like Biogen may be out of place but it makes the idea of the interest that big investors are demonstrating towards pharme and biotech companies in recent times. From what I see on Miracle Viewer, the indicator that analyzes the market in search of the capital of big players, many of the capital of big...

Sticky_green

www.bizjournals.com

dread003111

BIIB

Steve666

BIIB came out a nice Gartley Pattern on 4/22. First stop should be the $277 area as AB=CD, where I would think there will be some profit taking. Upside targets ($290+) are shown as this evolves into a possible Deep Crab Harmonic Pattern. Biogen needs FDA drug approval, descent earning against healthy market backdrop for this to happen. In higher time-frames...